<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Deferoxamine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Deferoxamine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Deferoxamine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11716" href="/d/html/11716.html" rel="external">see "Deferoxamine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13208" href="/d/html/13208.html" rel="external">see "Deferoxamine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F157271"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Desferal</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866530"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Desferal</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F157313"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidote;</li>
<li>
                        Chelating Agent</li></ul></div>
<div class="block doa drugH1Div" id="F157274"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c7d7e490-2979-41c0-bce0-3c3ea4e04728">Acute iron toxicity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute iron toxicity: Note:</b> The IV route is preferred and is used when severe toxicity is evidenced by cardiovascular collapse or systemic symptoms (coma, shock, metabolic acidosis, or gastrointestinal bleeding) or potentially severe intoxications (peak serum iron level &gt;500 mcg/dL) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Perrone.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Perrone.1'])">Ref</a></span>). The IM route may be used (per the manufacturer) but is not preferred and rarely indicated. The use of deferoxamine in situations in which the peak serum iron concentration is &lt;500 mcg/dL and when severe toxicity is not evident is a subject of clinical debate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.2015','lexi-content-ref-Perrone.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.2015','lexi-content-ref-Perrone.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, IV:</b> Initial: 1 g, may be followed by 500 mg every 4 hours for 2 doses; subsequent doses of 500 mg have been administered every 4 to 12 hours based on clinical response (maximum recommended dose: 6 g/day [per manufacturer]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c97fe51c-3192-45ea-973e-5f2d165cf97d">Chronic iron overload</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic iron overload: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> 500 mg to 1 g/day (maximum: 1 g/day).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 40 to 50 mg/kg/day (maximum: 60 mg/kg/day) over 8 to 12 hours for 5 to 7 days per week.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> 1 to 2 g/day or 20 to 40 mg/kg/day (maximum: 60 mg/kg/day) over 8 to 24 hours for 5 to 7 days per week.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing:</i>
<b>IV, SUBQ:</b> 25 to 50 mg/kg over 8 to 10 hours 5 to 7 days per week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21226580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21226580'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6a837eb8-ffd1-4e5d-8535-62da41b2a850">Diagnosis of aluminum-induced toxicity with CKD</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnosis of aluminum-induced toxicity with CKD (off-label use)</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14520607']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14520607'])">Ref</a></span>)<b>: IV</b>: Test dose: 5 mg/kg during the last hour of dialysis if baseline serum aluminum concentrations are 60 to 200 mcg/L, or clinical signs/symptoms of toxicity, or aluminum exposure prior to parathyroid surgery. Measure aluminum just prior to deferoxamine; remeasure 2 days later (test is positive if serum aluminum increases by ≥50 mcg/L). Do not use if unstimulated aluminum serum concentrations are &gt;200 mcg/L to avoid deferoxamine-induced neurotoxicity.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="97ba1ece-51e2-4a1d-8e69-08538dba16f1">Treatment of aluminum toxicity with CKD</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Treatment of aluminum toxicity with CKD (off-label use)</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14520607']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14520607'])">Ref</a></span>)<b>: IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Administer after diagnostic deferoxamine test dose. <b>Note:</b> The risk for deferoxamine-associated neurotoxicity is increased if unstimulated aluminum serum concentrations are &gt;200 mcg/L; do not perform the deferoxamine-stimulation test and administer intensive dialysis until &lt;200 mcg/L.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>If the serum aluminum concentration rises to ≥300 mcg/L two days after the deferoxamine test dose <b>or</b> there are side effects after the deferoxamine-stimulation test:</i> 5 mg/kg once a week 5 hours before dialysis for 4 months. Then discontinue deferoxamine for one month and perform the deferoxamine-stimulation test again.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>If the serum aluminum concentration is &lt;300 mcg/L two days after the deferoxamine test dose <b>and </b>there are no side effects after the deferoxamine-stimulation test:</i> 5 mg/kg once a week during the last hour of dialysis for 2 months. The discontinue deferoxamine for one month and perform the deferoxamine-stimulation test again.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990060"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Severe renal disease or anuria: Use is contraindicated in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">The following adjustments have been used by some clinicians (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>): Adults:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;50 mL/minute: No adjustment required</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 10 to 50 mL/minute, CRRT: Administer 25% to 50% of normal dose</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl&lt;10 mL/minute, hemodialysis, peritoneal dialysis: Avoid use</p></div>
<div class="block doha drugH1Div" id="F50987313"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Initiate at the lower end of the dosing range.</p></div>
<div class="block doe drugH1Div" id="F157275"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. May initiate at the lower end of the dosing range.</p></div>
<div class="block dop drugH1Div" id="F157293"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13208" href="/d/html/13208.html" rel="external">see "Deferoxamine: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0486db5a-cea8-428c-ae50-b5a9ff977aec">Acute iron intoxication</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute iron intoxication:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> The IV route is preferred and is used when severe toxicity is evidenced by cardiovascular collapse or systemic symptoms (coma, shock, metabolic acidosis, or GI bleeding) or potentially severe intoxications (peak serum iron level &gt;500 mcg/dL) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Perrone.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Perrone.1'])">Ref</a></span>). The IM route may be used (per the manufacturer) but is not preferred and rarely indicated. The use of deferoxamine in situations in which the peak serum iron concentration is &lt;500 mcg/dL and when severe toxicity is not evident is a subject of clinical debate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.2015','lexi-content-ref-31976760','lexi-content-ref-Perrone.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.2015','lexi-content-ref-31976760','lexi-content-ref-Perrone.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous IV infusion: Infants, Children, and Adolescents: Continuous IV infusion: Initial: 15 mg/kg/hour and reduce rate as clinically indicated; maximum daily dose: 80 mg/kg/<b>day</b> and not to exceed 6 <b>g</b>/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-Howland.2015','lexi-content-ref-19433938']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-Howland.2015','lexi-content-ref-19433938'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">IV: Infants, Children, and Adolescents: IV: Initial: 20 mg/kg (maximum dose: 1,000 mg/dose) administered no faster than 15 mg/kg/hour followed by 10 mg/kg (maximum dose: 500 mg/dose) over 4-hour intervals for 2 doses; subsequent doses of 10 mg/kg (maximum dose: 500 mg/dose) over 4 to 12 hours may be repeated depending upon the clinical response; maximum daily dose: 6 <b>g</b>/<b>day</b>; this dosing may also be used IM if symptoms not severe (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2361339','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2361339','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">IM: Children and Adolescents: IM: 90 mg/kg/dose for one dose, then 45 mg/kg/dose every 4 to 12 hours as needed; maximum single dose: Children: 1,000 mg/dose; Adults: 2,000 mg/dose; maximum daily dose: 6 <b>g</b>/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Desferal.5']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Desferal.5'])">Ref</a></span>); others have used 50 mg/kg/dose every 6 hours with maximum daily dose: 6 <b>g/day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21975503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21975503'])">Ref</a></span>); may also use intermittent IV dosing (see above).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c97fe51c-3192-45ea-973e-5f2d165cf97d">Chronic iron overload</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic iron overload:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>General dosing:</i></p>
<p style="text-indent:-2em;margin-left:6em;">IV:</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥3 years and Growing Adolescents: IV: 20 to 40 mg/kg/day over 8 to 12 hours, 5 to 7 days per week, usual maximum daily dose: 40 mg/kg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents once growth has ceased: 40 to 50 mg/kg/day over 8 to 12 hours, 5 to 7 days per week, usual maximum daily dose: 60 mg/kg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">SUBQ: Children ≥3 years and Adolescents: SUBQ infusion via a portable, controlled infusion device: 20 to 40 mg/kg/day over 8 to 12 hours 3 to 7 days per week; maximum daily dose: 2,000 mg/<b>day</b>. Doses &gt;60 mg/kg/day have not been shown to provide additional benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18671700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18671700'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Sickle cell disease, chronic iron overload:</i> Children and Adolescents: SUBQ infusion: 25 mg/kg/day over 8 hours; dose and duration may be increased as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NHLBI.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NHLBI.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Thalassemia, chronic iron overload:</i>
<b> Note:</b> A lower dose may be required if the ferritin levels are low. In general, the therapeutic index should be kept &lt;0.025 at all times. Therapeutic index = mean daily deferoxamine dose (mg/kg)/ferritin (mcg/L) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cappellini.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cappellini.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Growing Adolescents: SUBQ infusion: 20 to 40 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 40 mg/kg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents once growth has ceased:</p>
<p style="text-indent:-2em;margin-left:8em;">SUBQ infusion (preferred): 40 to 60 mg/kg/day over 8 to 12 hours, 6 to 7 nights per week, maximum daily dose: 2,000 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">SUBQ bolus: 45 mg/kg/dose, 5 times per week.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e0fac8f8-80f1-438a-9fd8-83eb121bbd48">Aluminum-induced bone disease in chronic renal failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aluminum-induced bone disease in chronic renal failure:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Intended for predialysis serum aluminum concentration of 60 to 200 mcg/L; do not start chelation therapy if serum aluminum concentration &gt;200 mcg/L; intensive dialysis (6 days per week with a high flux dialysis membrane) should be used until serum aluminum concentration decreases below 200 mcg/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14520607']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14520607'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Test (diagnostic) dose: IV: 5 mg/kg as a single dose infused over the last hour of dialysis; measure serum aluminum concentration 2 days later; depending upon the change in serum aluminum concentration, treatment with deferoxamine may be indicated (see Treatment below).</p>
<p style="text-indent:-2em;margin-left:8em;">Treatment: Monitor serum aluminum levels closely. See National Kidney Foundation guidelines for additional details on treatment algorithms.</p>
<p style="text-indent:-2em;margin-left:10em;">Aluminum serum concentration rise to ≥300 mcg/L or adverse effects with test dose: IV: 5 mg/kg once a week 5 hours before dialysis for 4 months.</p>
<p style="text-indent:-2em;margin-left:10em;">Aluminum serum concentration rise to &lt;300 mcg/L: IV: 5 mg/kg once a week during the last hour of dialysis for 2 months.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51090537"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Manufacturer's labeling: Severe renal disease or anuria: Use is contraindicated; in adults with impairment, dosage adjustment is suggested.</p></div>
<div class="block dohp drugH1Div" id="F51090538"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (not studied).</p></div>
<div class="block adr drugH1Div" id="F157244"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension, shock, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Growth retardation (children)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress, abdominal pain, diarrhea, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Dysplasia (metaphyseal), leukopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic impairment, increased serum transaminases</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (including anaphylactic shock), angioedema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (including <i>Yersinia</i> infections and mucormycosis)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (including burning sensation at injection site, crusted skin, erythema at injection site, induration at injection site, injection-site pruritus, irritation at injection site, localized vesiculation, pain at injection site, swelling at injection site, urticaria at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, headache, neuropathy (peripheral motor neuropathy, peripheral neuropathy, peripheral sensory neuropathy, and polyneuropathy), paresthesia, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, muscle spasm, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, cataract, corneal opacity, decreased peripheral vision, decreased visual acuity, night blindness, optic neuritis, retinal pigment changes, scotoma, vision color changes (including chromatopsia), vision loss, visual field defect</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Hearing loss (including high frequency hearing loss and sensorineural hearing loss), tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury, increased serum creatinine, renal failure syndrome, renal tubular disease</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute respiratory distress syndrome, asthma</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F157258"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to deferoxamine or any component of the formulation; patients with severe renal disease or anuria</p></div>
<div class="block war drugH1Div" id="F157241"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute respiratory distress syndrome (ARDS): Deferoxamine has been associated with ARDS following excessively high-dose IV treatment of acute iron intoxication or thalassemia; has been reported in children and adults.</p>
<p style="text-indent:-2em;margin-left:4em;">• Auditory effects: Auditory disturbances (tinnitus and high frequency hearing loss) have been reported following prolonged administration, at high doses, or in patients with low ferritin levels; effects are generally reversible with early detection and immediate discontinuation. Elderly patients are at increased risk for hearing loss. Audiology exams are recommended with long-term treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Growth retardation: High deferoxamine doses and concurrent low ferritin levels are also associated with growth retardation. Growth velocity may partially resume to pretreatment rates after deferoxamine dose reduction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Patients with iron overload are at increased susceptibility to infection with <i>Yersinia enterocolitica</i> and <i>Yersinia pseudotuberculosis;</i> treatment with deferoxamine may enhance this risk; if infection develops, discontinue therapy until resolved.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reactions: Flushing of the skin, hypotension, urticaria, and shock are associated with rapid IV infusion; administer by slow IV infusion, IM, or slow subcutaneous infusion only.</p>
<p style="text-indent:-2em;margin-left:4em;">• Mucormycosis: Rare and serious cases of mucormycosis (including fatalities) have been reported with use; withhold treatment with signs and symptoms of mucormycosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular effects: Ocular disturbances (blurred vision; cataracts; corneal opacities; decreased visual acuity; impaired peripheral, color, and night vision; optic neuritis; retinal pigment abnormalities; retinopathy; scotoma; visual loss/defect) have been reported following prolonged administration, at high doses, or in patients with low ferritin levels; effects are generally reversible with early detection and immediate discontinuation. Elderly patients are at increased risk for ocular disorders. Periodic ophthalmic exams are recommended with long-term treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal effects: Increases in serum creatinine, acute renal failure and renal tubular disorders have been reported; monitor for changes in renal function. Deferoxamine is readily dialyzable. When iron is chelated with deferoxamine, the chelate is water-soluble and is excreted renally.</p>
<p style="text-indent:-2em;margin-left:4em;">• Urine discoloration: Patients should be informed that urine may have a pink, reddish, or orange discoloration (often referred to as <i>vin rosé</i> discoloration).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aluminum toxicity: Treatment with deferoxamine in patients with aluminum toxicity may cause hypocalcemia and aggravate hyperparathyroidism. Deferoxamine may cause neurological symptoms (including seizure) in patients with aluminum-related encephalopathy receiving dialysis and may precipitate dialysis dementia onset.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemochromatosis: Deferoxamine is <b>not</b> indicated for the treatment of primary hemochromatosis (treatment of choice is phlebotomy).</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use may worsen or precipitate new myasthenia gravis (AAN [Narayanaswami 2021]; Krishnan 1995).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Ascorbic acid: Combination treatment with ascorbic acid (&gt;500 mg/day in adults) and deferoxamine may impair cardiac function (rare), effects are reversible upon discontinuation of ascorbic acid. If combination treatment is warranted, initiate ascorbic acid only after one month of regular deferoxamine treatment, do not exceed ascorbic acid dose of 200 mg/day for adults (in divided doses), 100 mg/day for children ≥10 years of age, or 50 mg/day in children &lt;10 years of age; monitor cardiac function. Do not administer deferoxamine in combination with ascorbic acid in patients with preexisting cardiac failure.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878409"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Growth retardation in pediatric patients especially in patients ≤3 years has been associated with high doses (&gt;60 mg/kg) and concurrent low ferritin levels; a reduction in deferoxamine dosage may partially improve growth velocity; monitor growth in children receiving chronic therapy closely.</p></div>
<div class="block foc drugH1Div" id="F157252"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection, as mesylate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Desferal: 500 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg (1 ea); 2 g (1 ea)</p></div>
<div class="block geq drugH1Div" id="F157237"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F157260"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Deferoxamine Mesylate Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g (per each): $37.20 - $62.16</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $15.54</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Desferal Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $41.67</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866531"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection, as mesylate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Desferal: 500 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg (1 ea); 2 g (1 ea)</p></div>
<div class="block adm drugH1Div" id="F157255"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Urticaria, flushing of the skin, hypotension, and shock have occurred following rapid IV administration; limiting infusion rate to 15 mg/kg/hour may help avoid infusion-related adverse effects.</p>
<p style="text-indent:-2em;margin-left:4em;">Acute iron toxicity: The IV route is generally preferred in patients with severe toxicity (ie, patients in shock). For the first 1 g, infuse at 15 mg/kg/hour (although rates up to 40 mg/kg/hour have been recommended in patients with severe iron intoxication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7837315','lexi-content-ref-Wright.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7837315','lexi-content-ref-Wright.1'])">Ref</a></span>)). Subsequent doses may be given over 4 to 12 hours at a rate not to exceed 125 mg/hour.</p>
<p style="text-indent:-2em;margin-left:4em;">Chronic iron overload: Administer over 8 to 12 hours for 5 to 7 days per week; rate not to exceed 15 mg/kg/hour. In patients with poor compliance, deferoxamine may be administered on the same day of blood transfusion, either prior to or following transfusion; do not administer concurrently with transfusion. Longer infusion times (24 hours) and IV administration may be required in patients with severe cardiac iron deposition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21226580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21226580'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Diagnosis or treatment of aluminum-induced toxicity with CKD: Administer dose over 1 hour, during the last hour of dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14520607']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14520607'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>SUBQ:</b> When administered for chronic iron overload, administration over 8 to 12 hours for 5 to 7 days per week using a portable infusion pump is generally recommended; however, longer infusion times (24 hours) may also be used. Topical anesthetic or glucocorticoid creams may be used for induration or erythema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21226580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21226580'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> IM administration may be used for patients with acute iron toxicity that do not exhibit severe symptoms (per the manufacturer), but the IV route is preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Perrone.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Perrone.1'])">Ref</a></span>); may also be used in the treatment of chronic iron toxicity.</p></div>
<div class="block admp drugH1Div" id="F52612489"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Preferred route of administration for acute iron ingestion in patients not in shock per the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Administer as intermittent IV infusion or as continuous IV infusion; maximum rate: 15 mg/kg/hour; may consider reducing infusion rate to &lt;125 mg/hour after the first 1,000 mg have been infused.</p>
<p style="text-indent:-2em;margin-left:4em;">SUBQ: When administered for chronic iron overload, administration over 8 to 12 hours using a portable infusion pump is generally recommended; however, longer infusion times (24 hours) may also be used. Topical anesthetic or glucocorticoid creams may be used for induration or erythema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21226580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21226580'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F157253"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute iron toxicity: </b>Adjunct in the treatment of acute iron intoxication</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic iron overload: </b>Treatment of chronic iron overload secondary to multiple transfusions (often due to the presence of thalassemia major or sickle cell disease [Borgna-Pignatti 2015; Marsella 2015])</p></div>
<div class="block off-label drugH1Div" id="F25475164"><span class="drugH1">Use: Off-Label: Adult</span><p>Diagnosis or treatment of aluminum-induced toxicity associated with chronic kidney disease (CKD)</p></div>
<div class="block mst drugH1Div" id="F157321"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Deferoxamine may be confused with cefuroxime, deferasirox, deferiprone</p>
<p style="text-indent:-2em;margin-left:4em;">Desferal may be confused with desflurane, Desyrel, Dexferrum</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Desferal [US, Canada, and multiple international markets] may be confused with Deseril brand name for methysergide [Australia, Belgium, Great Britain, Netherlands]; Disophrol brand name for dexbrompheniramine and pseudoephedrine [Czech Republic, Poland, Turkey]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299129"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F157246"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ascorbic Acid: May enhance the adverse/toxic effect of Deferoxamine. Left ventricular dysfunction is of particular concern. Management: Limit the ascorbic acid dose to 200 mg/day (given in divided doses) in adult patients. In general, limit ascorbic acid to 50 mg daily for pediatric patients under 10 years old and 100 mg daily for older pediatric patients.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betibeglogene Autotemcel: Iron Chelators may diminish the therapeutic effect of Betibeglogene Autotemcel.  Management: Avoid use of iron chelators for at least 7 days prior to conditioning therapy preceding betibeglogene autotemcel treatment, and avoid use of myelosuppressive iron chelators for at least 6 months after betibeglogene autotemcel.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exagamglogene Autotemcel: Iron Chelators may enhance the myelosuppressive effect of Exagamglogene Autotemcel. Iron Chelators may diminish the therapeutic effect of Exagamglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gallium Citrate Ga-67: Deferoxamine may diminish the diagnostic effect of Gallium Citrate Ga-67.  Management: Discontinue deferoxamine 48 hours prior to scintigraphy with gallium citrate Ga-67.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovotibeglogene Autotemcel: Iron Chelators may enhance the myelosuppressive effect of Lovotibeglogene Autotemcel. Iron Chelators may diminish the therapeutic effect of Lovotibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Deferoxamine. Management: Avoid ascorbic acid doses greater than 200 mg/day. Lower doses may be given to patients without cardiac failure, after one month of regular treatment with deferoxamine alone, ideally soon after setting up the infusion pump. Monitor cardiac function.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Deferoxamine. Left ventricular dysfunction is of particular concern. Management: Avoid ascorbic acid doses greater than 200 mg/day. Lower doses may be given to patients without cardiac failure, after one month of regular treatment with deferoxamine alone, ideally soon after setting up the infusion pump. Monitor cardiac function.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May enhance the adverse/toxic effect of Deferoxamine. Management: Avoid ascorbic acid doses greater than 200 mg/day. Lower doses may be given to patients without cardiac failure, after one month of regular treatment with deferoxamine alone, ideally soon after setting up the infusion pump. Monitor cardiac function.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prochlorperazine: Deferoxamine may enhance the adverse/toxic effect of Prochlorperazine. Specifically, prolonged loss of consciousness has been reported.  Management: Consider alternatives to prochlorperazine in patients receiving deferoxamine, due to a risk of temporary impairment of consciousness (potentially lasting for days) with the combination.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F802788"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline">Adverse events have been observed in animal reproduction studies. Toxic amounts of iron or deferoxamine have not been noted to cross the placenta; however, the metabolic effects of a maternal overdose may adversely affect the fetus. In case of acute iron toxicity, treatment during pregnancy should not be withheld (Chang 2011). </p></div>
<div class="block brc drugH1Div" id="F13811879"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if deferoxamine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">One patient who received deferoxamine during lactation for beta thalassemia exhibited normal breast milk iron concentrations. Adverse events were not reported in her breastfed twins (Surbek 1998). The manufacturer recommends that caution be exercised when administering to breastfeeding women.</p></div>
<div class="block dic drugH1Div" id="F802790"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline">Vitamin C supplements may need to be limited. The manufacturer recommends a maximum ascorbic acid dose of 200 mg/day in adults (given in divided doses), 100 mg/day in children ≥10 years of age, or 50 mg/day in children &lt;10 years of age. Avoid concurrent use with ascorbic acid in patients with heart failure. </p></div>
<div class="block mop drugH1Div" id="F157250"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum iron, ferritin, total iron-binding capacity, CBC with differential, renal function tests (serum creatinine), liver function tests, serum chemistries; ophthalmologic exam (visual acuity tests, fundoscopy, slit-lamp exam) and audiometry with long-term treatment; growth and body weight in children (every 3 months). When deferoxamine complexes with iron it forms a water-soluble compound (ferrixoamine) that imparts discoloration of the urine; often described as vin rosé (dark pink) discoloration to the urine (Fernández 2014). However, other than being aware of that it may occur, its presence or absence should not be used as a therapeutic endpoint.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Dialysis patients: Serum aluminum (yearly; every 3 months in patients on aluminum-containing medications)</p>
<p style="text-indent:-2em;margin-left:2em;">Aluminum-induced bone disease: Serum aluminum concentration 2 days following deferoxamine test dose; test is considered positive if the serum aluminum increases ≥50 mcg/L</p></div>
<div class="block rer drugH1Div" id="F802987"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Iron, serum: Normal: 50 to 160 mcg/dL; peak levels &gt;500 mcg/dL may be associated with toxicity. Consider treatment in symptomatic patients with levels ≥350 mcg/dL; toxicity cannot be excluded with serum iron levels &lt;350 mcg/dL</p>
<p style="text-indent:-2em;margin-left:2em;">Aluminum, serum: &lt;20 mcg/L recommended baseline level in dialysis patients (K/DOQI 2003)</p></div>
<div class="block pha drugH1Div" id="F157240"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Complexes with trivalent ions (ferric ions), primarily in the vascular space, to form ferrioxamine, which is eliminated in the urine by the kidneys. One hundred milligrams of deferoxamine will bind about 8.5 mg of free circulating elemental iron (85 mg per 1,000 mg dose) but does not remove iron from transferrin or hemoglobin. Binding of cytoplasmic free iron reduces the free iron-induced disruption of mitochondrial cell membranes and enzyme systems. Ferrioxamine may create a pink- to red- or orange-colored urine as it is being excreted; however, the presence or absence of urine discoloration should not be used as a therapeutic endpoint.</p></div>
<div class="block phk drugH1Div" id="F157257"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: IM, SUBQ: Well absorbed</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Distributed throughout body fluids</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &lt;10%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Plasma enzymes; binds with iron to form ferrioxamine (iron complex)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 14 hours; plasma: 20 to 30 minutes (Brittenham 2011)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily urine (as unchanged drug and ferrioxamine); feces (via bile)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F157261"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Deferoxamina richet | Desferal</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Desferal | Desferrioxamine</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Desferal | Desferal ciba | Mesilato de desferroxamina</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Deferoxaminmesilat | Desferal</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Desferin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Desferal | Desferrioxamin | Desferrioxamine</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Demoferidon</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Deferoxamina noridem | Desferal</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Deferoxamine | Desferal | Pfizer deferoxamine mesylate</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Desferal | Desferin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Desferal | Desferrioxamine</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Desferrioxamine</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Desferal | Desferrioxamine mesilate</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Deferoxamine mesylate | Desferal Mesylate</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Desferal | Ferioxin</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Desferal | Froxa</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Desferrioxamine</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Desferal | Talifer</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Desferal</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3620295">
<a name="3620295"></a>Allain P, Mauras Y, Chaleil D, et al. Pharmacokinetics and Renal Elimination of Desferrioxamine and Ferrioxamine in Healthy Subjects and Patients With Haemochromatosis. <i>Br J Clin Pharmacol</i>. 1987;24(2):207-212.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/3620295/pubmed" id="3620295" target="_blank">3620295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007, p 116.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21452290">
<a name="21452290"></a>Bacon BR, Adams PC, Kowdley KV, et al. Diagnosis and Management of Hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Disease. <i>Hepatology</i>. 2011;54(1):328-343.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/21452290/pubmed" id="21452290" target="_blank">21452290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26519233">
<a name="26519233"></a>Borgna-Pignatti C, Marsella M. Iron Chelation in Thalassemia Major. <i>Clin Ther</i>. 2015;37(12):2866-2877.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/26519233/pubmed" id="26519233" target="_blank">26519233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21226580">
<a name="21226580"></a>Brittenham GM. Iron-Chelating Therapy for Transfusional Iron Overload. <i>N Engl J Med</i>. 2011;364(2):146-156.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/21226580/pubmed" id="21226580" target="_blank">21226580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cappellini.1">
<a name="Cappellini.1"></a>Cappellini MD, Cohen A, Eleftheriou A, et al. Guidelines for the Clinical Management of Thallassemia. 2nd ed. Nicosia, Cyprus: Thalassaemia International Federation. November 2008. http://www.thalassaemia.org.cy/pdf/Guidelines_2nd_revised_edition_EN.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21975503">
<a name="21975503"></a>Chang TPY, Rangan C. Iron Poisoning-A Literature-Based Review of Epidemiology, Diagnosis, and Management. <i>Pediatr Emerg Care</i>. 2011;27(10):978-985.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/21975503/pubmed" id="21975503" target="_blank">21975503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7837315">
<a name="7837315"></a>Cheney K, Gumbiner C, Benson B, Tenenbein M. Survival after a severe iron poisoning treated with intermittent infusions of deferoxamine. <i>J Toxicol Clin Toxicol</i>. 1995;33(1):61-66. doi:10.3109/15563659509020217<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/7837315/pubmed" id="7837315" target="_blank">7837315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669553">
<a name="28669553"></a>Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. <i>Ann Emerg Med</i>. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/28669553/pubmed" id="28669553" target="_blank">28669553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Deferoxamine.1">
<a name="Deferoxamine.1"></a>Deferoxamine Mesylate (injection, USP) [prescribing information]. Weston, FL: Apotex Corp; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Deferoxamine.2">
<a name="Deferoxamine.2"></a>Deferoxamine mesylate for injection [prescribing information]. Kirkland, Quebec, Canada: Pfizer Canada Inc; July 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Desferal.1">
<a name="Desferal.1"></a>Desferal (deferoxamine) [product monograph]. Dorval, QC: Novartis Pharmaceuticals Canada Inc; May 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Desferal.2">
<a name="Desferal.2"></a>Desferal (deferoxamine) [product monograph]. Dorval, QC: Novartis Pharmaceuticals Canada Inc; July 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Desferal.3">
<a name="Desferal.3"></a>Desferal (deferoxamine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Desferal.4">
<a name="Desferal.4"></a>Desferal (deferoxamine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Desferal.5">
<a name="Desferal.5"></a>Desferal (deferoxamine) [summary of product characteristics]. London, United Kingdom: Novartis Pharmaceuticals UK Limited; July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NHLBI.1">
<a name="NHLBI.1"></a>Division of Blood Diseases and Resources, NHLBI. The Management of Sickle Cell Disease. National Heart, Lung, and Blood Institute; 2002. <a href="http://www.nhlbi.nih.gov/health/prof/blood/sickle/sc_mngt.pdf" target="_blank">http://www.nhlbi.nih.gov/health/prof/blood/sickle/sc_mngt.pdf</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24072332">
<a name="24072332"></a>Fernández S, Castro P, Nogué S, Nicolás JM. Acute iron intoxication: change in urine color during chelation therapy with deferoxamine. <i>Intensive Care Med</i>. 2014;40(1):104.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/24072332/pubmed" id="24072332" target="_blank">24072332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Howland.2015">
<a name="Howland.2015"></a>Howland MA. Antidotes in depth. In: <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. Nelson LS, Howland MA, Lewin NA, et al, eds. McGraw-Hill; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1742962">
<a name="1742962"></a>Kirking MH. Treatment of Chronic Iron Overload. <i>Clin Pharm</i>. 1991;10(10):775-783.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/1742962/pubmed" id="1742962" target="_blank">1742962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2361339">
<a name="2361339"></a>Klein-Schwartz W, Oderda GM, Gorman RL, Favin F, Rose SR. Assessment of management guidelines. Acute iron ingestion. <i>Clin Pediatr (Phila)</i>. 1990;29(6):316-321. doi:10.1177/000992289002900604<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/2361339/pubmed" id="2361339" target="_blank">2361339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7628591">
<a name="7628591"></a>Krishnan K, Trobe JD, Adams PT. Myasthenia gravis following iron chelation therapy with intravenous desferrioxamine. <i>Eur J Haematol</i>. 1995;55(2):138-139. doi:10.1111/j.1600-0609.1995.tb01826.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/7628591/pubmed" id="7628591" target="_blank">7628591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14520607">
<a name="14520607"></a>K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Guideline 6. Serum Calcium and Calcium-Phosphorus Product. http://www2.kidney.org/professionals/KDOQI/guidelines_bone/Guide6.htm
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/14520607/pubmed" id="14520607" target="_blank">14520607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lawson.1">
<a name="Lawson.1"></a>Lawson MK, Valko M, Cronin MT, Jomová K. Chelators in Iron and Copper Toxicity. <i>Curr Pharmacol Rep.</i> 2016;2(6):271-280.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31976760">
<a name="31976760"></a>Leonard JB, Hines EQ, Klein-Schwartz W. Iron packaging regulations in the United States and pediatric morbidity: A retrospective cohort study. <i>Clin Pediatr (Phila)</i>. 2020;59(4-5):375-379. doi:10.1177/0009922819901010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/31976760/pubmed" id="31976760" target="_blank">31976760</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16255338">
<a name="16255338"></a>Manoguerra AS, Erdman AR, Booze LL, et al. Iron Ingestion: An Evidence-Based Consensus Guideline for Out-of-Hospital Management. <i>Clin Toxicol (Phila)</i>. 2005;43(6):553-570.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/16255338/pubmed" id="16255338" target="_blank">16255338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25064709">
<a name="25064709"></a>Marsella M, Borgna-Pignatti C. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease. <i>Hematol Oncol Clin North Am</i>. 2014;28(4):703-727.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/25064709/pubmed" id="25064709" target="_blank">25064709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33144515">
<a name="33144515"></a>Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. <i>Neurology</i>. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/33144515/pubmed" id="33144515" target="_blank">33144515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NHLBI.2">
<a name="NHLBI.2"></a>National Heart, Lung, and Blood Institute (NHLBI). The Management of Sickle Cell Disease. Publication no. 02-2117. 2005.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14520607">
<a name="14520607"></a>National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. <i>Am J Kidney Dis</i>. 2003;42(4 Suppl 3):S1-S201.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/14520607/pubmed" id="14520607" target="_blank">14520607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Perrone.1">
<a name="Perrone.1"></a>Perrone J. Iron. In: <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. Nelson LS, Howland MA, Lewin NA, et al, eds. McGraw-Hill; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450. doi:10.1542/peds.2019-3450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24504090">
<a name="24504090"></a>Sheth S. Iron chelation: an update. <i>Curr Opinion Hematol</i>. 2014;21(3):179-185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/24504090/pubmed" id="24504090" target="_blank">24504090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8809281">
<a name="8809281"></a>Stiles ML, Allen LV, Prince SJ. Stability of Deferoxamine Mesylate, Floxuridine, Fluorouracil, Hydromorphone Hydrochloride, Lorazepam, and Midazolam Hydrochloride in Polypropylene Infusion-Pump Syringes. <i>Am J Health Syst Pharm</i>. 1996;53(13):1583-1588.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/8809281/pubmed" id="8809281" target="_blank">8809281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9773387">
<a name="9773387"></a>Surbek DV, Glanzmann R, Nars PW, Holzgreve W. Pregnancy and lactation in homozygous beta-thalassemia major. <i>J Perinat Med</i>. 1998;26(3):240-243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/9773387/pubmed" id="9773387" target="_blank">9773387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19433938">
<a name="19433938"></a>Valentine K, Mastropietro C, Sarnaik AP. Infantile Iron Poisoning: Challenges in Diagnosis and Management. <i>Pediatr Crit Care Med</i>. 2009;10(3):e31-e33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/19433938/pubmed" id="19433938" target="_blank">19433938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18671700">
<a name="18671700"></a>Vlachos A, Ball S, Dahl N, et al. Diagnosing and Treating Diamond Blackfan Anaemia: Results of an International Clinical Consensus Conference. <i>Br J Haematol</i>. 2008;142(6):859-876.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/deferoxamine-drug-information/abstract-text/18671700/pubmed" id="18671700" target="_blank">18671700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wright.1">
<a name="Wright.1"></a>Wright SW. Valento, M, Mazor SS, Chen, BC. Severe iron poisoning treated with prolonged deferoxamine infusion: a case report. <i>Toxicology Communications</i>. 2018;2(1):6-9. https://www.tandfonline.com/doi/full/10.1080/24734306.2018.1425280
                  </div>
</li></ol></div><div id="topicVersionRevision">Topic 9327 Version 241.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
